+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers



Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers



Current Hypertension Reports 4(5): 333-335




(PDF emailed within 0-6 h: $19.90)

Accession: 046870037

Download citation: RISBibTeXText

PMID: 12217250

DOI: 10.1007/s11906-002-0059-5


Related references

Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?. Internal Medicine Journal 46(3): 364-372, 2016

Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction. Journal of Clinical Hypertension 6(6): 315-23; Quiz 324-5, 2004

Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. Southern Medical Journal 102(10 Suppl): S1-S12, 2009

The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study. American Journal of Hypertension 11(11 Pt 2): 192s-194s, 1998

Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. Journal of Hypertension 23(5): 905-911, 2005

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opinion on Emerging Drugs 10(4): 729-745, 2005

New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. American Journal of Cardiology 100(3a): 45j-52j, 2007

The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. Reviews in Cardiovascular Medicine 3(4): 183-191, 2003

Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clinical Journal of the American Society of Nephrology 3(5): 1266-1273, 2008

Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. Journal of the Indian Medical Association 107(3): 178-182, 2009

Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. Journal of Hypertension 21(6): 1207-1211, 2003

The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease. Journal of the Renin-Angiotensin-Aldosterone System 13(3): 317-327, 2013

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology, Dialysis, Transplantation 26(9): 2827-2847, 2012

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. Isrn Cardiology 2013: 478597-478597, 2013

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vascular Health and Risk Management 7: 605-622, 2012